Elexacaftor/tezacaftor/ivacaftor’s effects on cystic fibrosis infections are maintained, but not increased, after 3.5 years of treatment
Sarah J. Morgan, Ellis Coulter, Hannah L Betts, George M. Solomon, John Clancy, Steven M. Rowe, David P. Nichols, Pradeep K. Singh
Topics & Concepts
IvacaftorCystic fibrosisMedicineBioinformaticsPhysiologyInternal medicineBiologyCystic fibrosis transmembrane conductance regulatorCystic Fibrosis Research Advances